Clinical trials: Monoclonal
Ulcerative Colitis, Gastrointestinal Disease
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis.
- Conditions
- Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
- Trial name
- NCT00073047
- Testing
- Daclizumab
- Where
- 35 sites in United States, Belgium and 1 more
- Volunteers
- 150 people
- Sponsor
- Facet Biotech
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278421
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in Germany, Israel and 1 more
- Volunteers
- 592 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Phase III
Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection in the Treatment of Moderate-to-Severe Active AS
This is a multicenter, randomized, double-blind, placebo-controlled, and parallel grouping study. Study procedures: The screening period does not exceed 4 weeks, including 16 weeks for initial treatment, 28 weeks for maintenance…
- Trial name
- NCT07498634
- Testing
- XKH004
- Where
- China
- Volunteers
- 323 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Dermatitis, Atopic, Eczema, Atopic
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
This is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of 611 when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination…
- Trial name
- NCT06554847
- Testing
- 611, Topical corticosteroid
- Where
- 3 sites in China
- Volunteers
- 417 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome
This phase I trial studies the side effects and best dose of iodine I 131monoclonal antibody BC8 when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, and donor bone marrow transplant, and to…
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, CD45-Positive Neoplastic Cells Present
- Trial name
- NCT00589316
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Fred Hutchinson Cancer Center
Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy followed by rituximab or observation in treating patients who have stage III or stage IV low-grade non-Hodgkin's lymphoma.
- Conditions
- Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Small Lymphocytic Lymphoma
- Trial name
- NCT00003204
- Testing
- cyclophosphamide, fludarabine phosphate, vincristine sulfate
- Where
- United States
- Volunteers
- 515 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Spontaneous Urticaria (CSU)
A Study of MG-K10 in Chronic Spontaneous Urticaria
This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial aimed at evaluating the efficacy and safety of MG-K10 humanized monoclonal antibody injection in CSU trial participants with poor…
- Trial name
- NCT07546487
- Testing
- MG-K10 Humanized Monoclonal Antibody Injection
- Volunteers
- 226 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program.
- Conditions
- Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Trial name
- NCT05831358
- Testing
- Multiple Myeloma M-Protein Analysis, Multiple Myeloma Knowledge Questionnaires
- Where
- United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Case Comprehensive Cancer Center
Hematological Malignancy
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab).
- Trial name
- NCT01084252
- Testing
- Isatuximab SAR650984, Dexamethasone
- Where
- 59 sites in United States, Argentina and 15 more
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Sanofi
AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors
The goal of this a retrospective real-world study is to compare the AKI events in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody (AntiVEGF) vs immune checkpoint inhibitors (ICIs).
- Trial name
- NCT06119347
- Testing
- AntiVEGF, ICIs
- Where
- China
- Volunteers
- 1,581 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Pregnancy Related, Immune-mediated Diseases
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development
What is this project about? This project aims to better understand how the immune system develops in babies whose mothers received immunomodulatory treatments during pregnancy.
- Trial name
- NEWbornIMMPACT (NCT07033663)
- Testing
- Monoclonal antibody
- Where
- 3 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Fundació Sant Joan de Déu
Crohn's Disease
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
To make adalimumab available to subjects suffering from moderately to severely active Crohn's Disease (CD) and to expand the safety information on adalimumab.
- Trial name
- ACCESS (NCT00427921)
- Testing
- adalimumab
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- Abbott
Gastric Cancer
Chemotherapy Combined With Apatinib and PD-1 Antibody
The effective rate of second-line and later-line single-agent therapy for advanced gastric cancer is limited. This research plan aims to explore whether the combination of drugs can further improve the benefits of second-line and…
- Trial name
- NCT05025033
- Testing
- PD-1 antibody, paclitaxel or irinotecan, Apatinib mesylate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
Dermatitis, Atopic
A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.
- Trial name
- NCT03754309
- Testing
- KY1005
- Where
- 19 sites in Germany, Poland and 2 more
- Volunteers
- 89 people
- Sponsor
- Kymab Limited
Colorectal Neoplasms
A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
This was a Phase 1, open-label, single-center study of CS-1008, an immunoglobulin G subclass 1 (IgG1) humanized monoclonal antibody, in subjects with advanced colorectal carcinoma who had received ≥ 1 prior chemotherapy regimen…
- Trial name
- NCT01220999
- Testing
- CS-1008
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Ludwig Institute for Cancer Research
SARS-CoV 2
Immune Responses to COVID-19; Isolation of Neutralizing Antibodies for Therapeutics and Vaccine.
According to different projections, the COVID-19 outbreak currently happening in France and worldwide could result in millions of deaths in the absence of efficient therapies.
- Trial name
- AcNT-COVID19 (NCT04596098)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 55 people
- Sponsor
- University Hospital, Grenoble
HER2-positive, Metastatic Breast Cancer
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).
- Trial name
- NCT05018702
- Testing
- ARX788
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Fudan University
Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
- Conditions
- Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Monoclonal B-Cell Lymphocytosis CLL-Type
- Trial name
- NCT05694312
- Testing
- Ibrutinib 420 mg
- Where
- 3 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Healthy Participants
An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab
The purpose of this study is to compare the pharmacokinetic (PK) exposures of a single subcutaneous (SC) dose of tozorakimab administered using AI or APFS in healthy participants.
- Trial name
- NCT06908577
- Testing
- Tozorakimab, Autoinjector (AI) Device, Accessorised Prefilled Syringe (APFS) Device
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.